Orexo Ab operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Orexo Ab with three other
pharmaceutical manufacturers in Europe:
COSMO Pharmaceuticals SA
sales of 67.24 million Euro [US$76.15 million]
of which 54%
was Manufacturing of MMX Products),
(336.90 million Romanian Leu [US$80.37 million]
Eco Animal Health Group Plc
based in the United Kingdom
(£61.42 million [US$79.15 million]
of which 100%
was Animal Health Product).
During the year ended December of 2017, sales at
Orexo Ab were SEK 643.70 million (US$69.51 million).
decrease of 8.8%
versus 2016, when the company's sales were SEK 705.90 million.
Contributing to the drop in overall sales was the 91.5% decline
in Zubsolv Non Us Upfront Payment, from SEK 65.90 million to SEK 5.60 million.
There were also decreases in sales in
Other Revenue/ R&d (down 46.6% to SEK 21.80 million)
However, these declines were partially offset by the increase in sales of
Zubsolv (up 0.8% to SEK 485.80 million)
Royalty - Abstral (up 12.7% to SEK 113.20 million)
Royalty - Edluar (up 16.9% to SEK 17.30 million)